Document K6bDwo7xXYjVXYy09wB1Q6YLx

To: @mmm.com] Cc: From: Sent: Subject: restrictiePFAS] @rivm.nl] BEEZ @demilieutafel.nl Mon 11/16/2020 3:45:05 PM RE: RE: 'PFAS and alternatives in medical devices and pharmaceuticals' study Received: Mon 11/16/2020 3:45:14 PM BE Dear It's a good idea to get acquainted a bit and discuss the focus of the Medical workpackage by phone. Around 15:00 p.m. tomorrow will suit me fine. Kind regards, 2965680 [EEE From: <BEAN (@ mmm. com> Sent: maandag 16 november 2020 14:52 To: @ EEE demilieutafel.nl Cc: 'restrictiePFAS' rivm.nl> JE Subject: RE: RE: 'PFAS and alternatives in medical devices and pharmaceuticals' study BEN Thank you very much for your reply. As said, 3M would indeed be interested to participate in this survey. Is there a full questionnaire that you could share with me, or are the two categories below (polymers and aerosols) the only ones you are looking at? We are fine with sharing data either in written form or by phone (or both). Before sharing any data with you, we would however need to put in place the Confidentiality Disclosure Agreement between 3M and De milieutafel -- | will take care of that and send you a draft CDA for your review and agreement. Perhaps we could have a quick introductory call to discuss these aspects in the coming days? I'm free tomorrow anytime except 10h30-11h30 and 13h-14h -- would tomorrow work for you? Best regards, Science. Applied to Life." Office: SEKECSN Hermeslaan 7 | 1831 Diegem (Brussels) Belgium | Mobile: @mmm.com | www.3M.com From: IEE 2 dc nmilicutafel.ni JBEM @ denilieutafel.ni> Sent: Monday 16 November 2020 08:24 To: < mmm.com:> Cc: 'restrictiePFAS' rivm.nl> Subject: [EXTERNAL] RE: 'PFAS and alternatives in medical devices and pharmaceuticals' study pearEXEEN, I am currently involved in making an overview of the medical use of per- and polyfluorinated substances. We can talk by phone, or exchange questions and answers by e-mail. | am aware that 3m also has provide information for the public consultation. | have to admit that | have not been able yet to evaluate this information. My questions are: Concerning polymers: * Which fluorinated polymer containing products do you produce? * Can you make a distinction in single use, reusable/durable and in-patient applications? * What are the amounts marketed in the EU and market values? * What are the main players, what is your market position? * Do you think that there are viable alternatives? What would be the consequence of restriction? BEN: Concerning aerosols (is this topic covered by a colleague of vou, k * Which per- and polyfluorinated aerosols do you bring on the market? * Are they seen as part ofa medical device or as a medicine, | mean how is the registration (do they fall within the scope of the Aerosol Dispenser Directive? * Can you give an indication of the amounts per treatment or total amounts on the (EU) market? * Do you think that there are viable alternatives? * What would be the consequence of restriction? 2965680 I will send my findings to RIVM in January 2021, who will include them in a larger report with other uses such as food contact materials, and others. Please do not hesitate to contact me. Kind regards, 5.1.2e Phone: +++ 5.1.2e JEN 2mm. From: com> Sent: donderdag 12 november 2020 16:26 [EE demilieutafel.n To: @ Subject: 'PFAS and alternatives in medical devices and pharmaceuticals' study Dear [EEE | have been given your contact by from Exponent. | understand you are the leading person in charge of the `PFAS and alternatives in medical devices and pharmaceuticals' study for the Dutch authorities. As you might know, 3M is one of the leading manufacturers of medical devices and we provided quite extensive information on the use of PFAS in our medical devices during the PFAS Call for Evidence in July this year. We would appreciate to participate in this follow-up study that you are conducting now on behalf of the Dutch authorities. Could you please let me know if it would be possible to include us in your study, what additional information are you looking for, and what is the timeframe of your research? Thank you in advance for your feedback. Best regards, Science. Applied to Life." Hermeslaan 7 | 1831 Diegem (Brussels) Belgium Office: | mobile: IEEE @mmm.com | www.3M.com